Standard dosage and individualized adjustment plan of sparsentan

Sparsentan (Sparsentan) is an oral dual receptor antagonist that mainly acts on angiotensin II receptor (A RB) and endothelin receptor (ERA), used to treat primary IgA nephropathy (IgAN) and other kidney diseases. By inhibiting both theRAAS and endothelin pathways, sparsentan reduces proteinuria, delays decline in renal function, and improves long-term patient outcomes. The drug provides a new treatment option for chronic disease management, especially for patients with high-risk proteinuria.

In clinical trials, the recommended starting dose of sparsentane is usually 200 mg taken orally once daily. In patients with good tolerance, the dose can be gradually increased to 400 mg once daily based on blood pressure control and proteinuria improvement to achieve optimal efficacy. The standard dosage is designed to balance efficacy and safety, ensuring that the drug reduces proteinuria without increasing the risk of hypotension or worsening of renal function.

For elderly patients or patients with impaired renal function (eGFR < 60 mL/min/1.73 m²), the starting dose may be appropriately reduced to 100–150mgonce daily to reduce the risk of hypotension or abnormal potassium levels. During treatment, blood pressure, renal function and electrolytes should be monitored regularly, and dosage adjustments should be made under the guidance of a doctor. If hypotension, elevated serum potassium, or significant decrease in renal function occurs, the dose should be suspended or reduced until the indicators return to normal.

During the use of sparsentane, patients need to maintain regular medication, avoid increasing or decreasing the dose on their own, and regularly review renal function, blood pressure, and blood electrolytes. The risk of hypotension and electrolyte imbalance should be carefully monitored when other antihypertensive agents or diuretics are used concomitantly. Through individualized dose adjustment and continuous monitoring, sparsentan can exert maximum efficacy while ensuring safety, and provide long-term and stable proteinuria control program for patients with primary IgA nephropathy.

Reference materials:https://www.drugs.com/